- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04880447
Special Investigation of COMIRNATY in the Population With Underlying Diseases
May 5, 2022 updated by: Pfizer
Special Investigation of COMIRNATY Intramuscular Injection (Investigation of Patients With Underlying Disease Considered to be at High Risk of Aggravation of COVID-19)
Post-marketing study, Cohort study of COMIRNATY vaccines.
To collect information on adverse events and COVID-19 observed after vaccination with COMIRNATY and to assess safety in patients with underlying disease considered to be at high risk of aggravation of COVID-19 who have received vaccination with this product under actual use conditions.
Study Overview
Detailed Description
This is a multicenter cohort study to be conducted in individuals with underlying diseases considered to be at high risk of aggravation of COVID-19 who are vaccinated with this product, and the investigator will enter the information required in this study in the case report forms (CRFs) based on the information obtained through preliminary examination sheet or medical interview, etc. and records such as medical records.
A health observation diary will be distributed to the subjects participating in this study and they will be requested to record information on local reactions and systemic reactions after vaccination with this product.
Study Type
Observational
Enrollment (Actual)
1075
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan, 1518589
- Pfizer Local County
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with underlying disease considered to be at high risk of aggravation of COVID-19 (Underlying diseases considered to be at high risk of aggravation of COVID-19 are based on the range of patients with underlying diseases indicated by the Ministry of Health, Labour and Welfare for priority vaccination.)
Description
Inclusion Criteria:
-Subjects who are able to understand the content of this study and to record their symptoms in the health observation diary, and who have provided written consent to participate in this survey by themselves (or parents or legal guardians in the case of minors)
Exclusion Criteria:
- There are no exclusion criteria for this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
COMIRNATY
COVID-19 mRNA vaccine
|
COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each).
It is recommended to administer the second dose 3 weeks after the first dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with Adverse reactions
Time Frame: From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
Number of subjects with Serious adverse reactions
Time Frame: From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
Proportion of subjects with Adverse reactions
Time Frame: From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
Proportion of subjects with Serious adverse reactions
Time Frame: From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
Proportion of subjects with local reaction and systemic events
Time Frame: From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
From the date of the first vaccination with COMIRNATY (Day 1) to 28 days after the second vaccination.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 26, 2021
Primary Completion (Actual)
April 14, 2022
Study Completion (Actual)
April 14, 2022
Study Registration Dates
First Submitted
May 5, 2021
First Submitted That Met QC Criteria
May 5, 2021
First Posted (Actual)
May 10, 2021
Study Record Updates
Last Update Posted (Actual)
May 10, 2022
Last Update Submitted That Met QC Criteria
May 5, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C4591019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on BNT162b2
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
BioNTech SEPfizerCompletedCOVID-19 | SARS-CoV-2 InfectionUnited States, Brazil, South Africa, Germany, Canada, Israel
-
BioNTech SEPfizerCompleted
-
BioNTech SEPfizerCompletedSARS-CoV-2 Infection, COVID-19United States, Spain, Finland, Poland, Mexico, Brazil
-
Universiteit AntwerpenCompletedCOVID-19 | Coronavirus Disease 2019Belgium
-
PfizerCompleted
-
The University of Hong KongRecruitingImmunocompromised Patients | Intradermal Covid-19 Vaccine | Immungenicity and Safety | Randomized TrialHong Kong
-
Murdoch Childrens Research InstituteCoalition for Epidemic Preparedness Innovations; The Peter Doherty Institute...Withdrawn
-
BioNTech SEPfizerCompletedCOVID-19 | SARS-CoV-2 InfectionUnited States
-
Shaare Zedek Medical CenterCompletedCOVID-19 | Myocardial Injury | Vaccine Adverse ReactionIsrael